Nutrition: Beyond Calcium and Vitamin D

Total Page:16

File Type:pdf, Size:1020Kb

Nutrition: Beyond Calcium and Vitamin D Acid Base Balance and Skeletal Health Nutrition: Beyond Calcium and Vitamin D Deborah E. Sellmeyer, MD Professor of Medicine • Acid precursors: sulfur containing amino acids in all proteins Division of Endocrinology, Gerontology, and Metabolism • Base precursors: alkaline potassium salts in fruit/vegetables Stanford University School of Medicine (Kcitrate, KHCO3) • Does exposure to a net dietary acid load mobilize base from bone to titrate dietary acid? Long-term Potential Effects of a Net Dietary Acid Load Relationship is Complex • Skeleton • Primary focus on protein (acid) – Physiochemical effect – Cell mediated • Protein only half the equation: hunter-gatherer diets – ~250 g/d protein • Muscle – typically net base producing – IGF-1 – Mobilization of glutamine • Hunter-gatherer diet = 88 meq/day base • Effects of age-related decline in renal function • Western diet = 58 meq/day acid • ? Net effect = bone / muscle loss Sebastian A et. al. Am J Clin Nutr. 2002 Dec;76(6):1308-16. Page 1 Sulfur-containing AA (g) per 10g Protein Improving Dietary Acid-Base Balance spaghetti noodles • Option 1: Less acid haddock white rice – Reduce dietary protein, cereal grains chicken – Protein important for peak bone mass, english muffin skeletal maintenance, healing ground beef cottage cheese • Option 2: More base milk – Dietary (potassium-rich fruit / veggies) soybeans Grt North beans – Alkaline potassium supplements peanut butter • Potassium bicarbonate peas • Potassium citrate almonds 0.00 0.10 0.20 0.30 0.40 KCitrate and Long-term Calcium Balance Study Procedures • Randomized (stratified by gender) to 6 months of: • Dietitian counseled and monitored self-selected – Placebo (n=18) diet to 600 mg/d – Potassium citrate 60 mmol/day (n=18) • Calcium and vitamin D – Potassium citrate 90 mmol/day (n=17) – 600 mg dietary calcium • NAE Western diet = 50-75 mmol/day – 630 mg calcium citrate • Baseline and Month 6 – 400 IU vitamin D – 12 days controlled diet • Two week run-in – Calcium balance: days 7-12 complete urine – Calcium 1230 mg/d (diet + supplements) and stool collections in 24 hour increments – Vitamin D 400 IU/d = dietary calcium intake – (urine calcium + fecal calcium) – Placebo (identical to KCitrate): 3 pills, 3 times / day – Fractional calcium absorption (oral / IV stable isotopes) Page 2 Subject Characteristics Net Acid Excretion Net acid excretion K Citrate K Citrate Placebo (meq/day) 60 mmol/day 90 mmol/day (n=18) (n=17) (n=17) 40 Age (years) 65.2 + 6.2 64.7 + 5.9 63.8 + 6.4 30 NAE = (Titratable Acid + NH ) – HCO 20 4 3 Gender (% female) 67% 67% 73% 10 Race (% Caucasian) 83% 100% 78% 0 BMI (g/m2) 26.0 + 4.0 25.1 + 2.7 24.3 + 3.3 -10 Placebo Urine calcium (mg/day) 184 + 59 206 + 94 189 + 82 -20 * KCitrate 60 mmol/day -30 KCitrate 90 mmol/day 25-hydroxyvitamin D (ng/ml) 36 + 10 31 + 10 32 + 10 -40 * No significant differences at baseline. *p<0.05 compared to placebo Calcium Absorption and Balance 6 Month Intervention Markers of Bone Turnover Change in urine calcium Change in fractional Change in calcium K Citrate K Citrate excretion (mg/day) calcium absorption (%) balance (mg/day) Placebo 60 mmol/day 90 mmol/day 40 10 250 * BsAP (μg/L) 20 8 200 Baseline 11.8 + 1.3 11.8 + 1.3 11.3 + 1.1 0 6 150 4 100 -20 Change -0.95 + 0.8 -1.1 + 0.9 -1.8 + 0.8 2 50 Serum CTX (ng/ml) -40 0 0 Baseline 0.19 + 0.04 0.25 + 0.03 0.25 + 0.04 -60 -2 -50 * a a -80 -4 -100 Change 0.04 + 0.03 -0.07 + 0.04 -0.03 + 0.04 -100 * -6 -150 a Placebo p<0.05 vs. placebo KCitrate 60 mmol/day *p<0.05 compared to placebo KCitrate 90 mmol/day Moseley KF, et al. J Bone Miner Res. 2013 Mar;28(3):497-504. Moseley KF, et al. J Bone Miner Res. 2013 Mar;28(3):497-504. Page 3 KCitrate and BMD KCitrate and BMD 0.0 161 postmenopausal women KCl 30 mmol/day KCitrate -0.5 -1.0 KCitrate 55.5 mmol + 1% + 1% -1.5 KCitrate 18.5 mmol 0% 0% 1.9% 2.0% Placebo p<0.001 p<0.001 -2.0 Fruit / Veggies - 1% - 1% -2.5 - 2% (%) change BMD 2-year -3.0 Lumbar Spine Total Hip 3 Months 6 Months 9 Months 12 Months 276 postmenopausal women Lumbar Spine Total Hip KCitrate 55.5 mmol/d, 18.5 mmol/d, fruit / veggies, placebo No effect BMD, urine calcium Jehle S, et. al. J Am Soc Nephrol. 2006 Nov;17(11):3213-22 Macdonald HM, et al. Am J Clin Nutr. 2008 Aug;88(2):465-74 L2-L4 3 n=91n=87 n=86 n=84 2.5 KCitrate and BMD 2 †† †† Isoflavones/Soy 1.0 † xx xx 1 xx 1.7% 0.5 (1.0-2.3) • Plant compounds (phytoestrogens) found in 0 N=201 -0.5 soybeans, clover, alfalfa sprouts n=91n=87 n=86 n=85 60% female % Change % Change in BMD -1 -1.5 25(OH)vit D = 24 + 8 ng/ml • Studies on bone health mixed -2 L Spine T-score = -0.6 + 1.5 0 6 12 18 24 – Interventions varied Months Kcitrate Placebo Kcitrate 60 mmol/day vs. pbo – Different compounds may offset each other 2 Total Hip NAE negative on Kcitrate – Effects may depend on proximity to menopause 1.5 n=91n=87 n=86 n=84 1 – Equol producers † † † 0.5 x x xx 1.0% ↑ trabecular thickness, – 2 placebo controlled RCTs neg 0 (0.5-1.5) -0.5 number on QCT. -1 n=90n=87 n=86 n=85 % Change % Change in BMD -1.5 -2 0 6 12 18 24 x=p<0.05; xx=p<0.001, Kcitrate vs. placebo Months Kcitrate †=p<0.05;††=p<0.001, compared to baseline Placebo Jehle S, et. al. J Clin Endocrinol Metab. 2013 Jan;98(1):207-17. Page 4 Sodium Chloride Phosphorus • dietary NaCl urine calcium, bone resorption Relationship • Essential for bone building and growth to Skeleton • 85% of body’s P bound to skeleton • Effects on fracture not known • Dietary K and base (fruit and vegetables) offset The Issues • Excess PO4 PTH ? bone resorption NaCl effects • Typical intakes > RDA (700 mg/day) • PO4 intake ’ing due to preservatives • High salt foods: • High dietary Ca absorption dietary PO4 – prepared foods--jars, cans, boxes, bottles Sources • Meat, poultry, fish, eggs, dairy, nuts, legumes, – condiments, sauces cereals, grains, cola – cheese, bread – restaurants Bottom Line • Typical intakes (1000-1500 mg/day) prob OK unless dietary Ca low • Current RDA: 1500mg/day; AHA rec: 2400mg/day • Poor overall nutrition = low PO4 intake • ? important during anabolic osteoporosis tx Magnesium Iron Relationship • Essential for bone formation Relationship to Skeleton • 2/3 of body’s Mg in skeleton (surface) • Co-factor for enzymes involved in collagen synthesis • Impt for proper crystal formation during mineralization to Skeleton The Issues • Deficiency impairs PTH secretion hypocalcemia, The Issues • bone strength Fe deficient rats vitamin D resistance • Fe absorption decreased by other minerals esp Ca • Typical intakes < RDA • Fe overload states associated with trabecular • RDA 320 mg women, 420 mg men, +35 mg preg volume, number, thickness Sources Sources • Whole grains, green vegetables, squash, nuts, seeds, • Dark green veg, spinach, red meat “hard” water Bottom Line • Separate Fe and calcium supplements • Unclear how much of bone deficits in overload states Bottom Line • Typical intakes appear low • EtOH Mg wasting due to Fe itself • Effect on skeletal health not clear Page 5 Zinc Copper Relationship • Co-factor for enzymes involved in collagen synthesis Relationship • Involved in collagen maturation, cross linking to Skeleton and mineralization to Skeleton The Issues • bone formation Zn deficient rats The Issues • Typical intakes < RDA • Low Zn levels associated with osteoporosis in humans • Cu deficiency assoc with osteoblast function • Zn supplements improved BMD in rats • Trace mineral supplement incl Cu increased BMD Sources • Red meat, poultry, fish, oysters, eggs, legumes, whole Sources • Legumes, nuts, mushrooms, liver, oysters, cereals, grain breads, milk chocolate Bottom Line • Zn stims osteoblasts, bone formation in animal studies Bottom Line • Need human intervention studies • EtOH Zn wasting • Need human intervention studies Vitamin A and Carotenoids Vitamin B12 Relationship • Vitamin A involved in bone remodeling process Relationship • May effect osteoblast function/activity to Skeleton • Animal foods: retinol; vegetables: carotenoids to Skeleton The Issues • Excess and deficiency Vit A skeletal fragility The Issues • Low serum B12 associated with BMD, bone loss, • intakes/ serum retinol levels associated with BMD, fracture in most human studies fracture in some human studies • Supplementation with B12 and folate in CVA • β-carotene, lycopene, leutein assoc with BMD, population hip fracture risk (RCT) bone loss, hip fracture Sources • Fish, shellfish, meat, poultry, eggs, milk Sources • red/orange/yellow vegetables (β-carotene), dark green veg (lutein), tomatoes, watermelon (lycopene), liver, Bottom Line • Be alert to states associated with B12 dairy products, fish – Vegan – Pernicious anemia Bottom Line • Avoid excess or insufficient Vit A intake (3000 IU per – Gastric bypass day in supplements) – Atrophic gastritis (up to 40% elderly) • Vegetable sources also provide antioxidants – Celiac, Crohn’s, other GI disease Page 6 Vitamin C Vitamin K Relationship • Required for collagen crosslinking Relationship • Co-enzyme for carboxylase enzyme to Skeleton to Skeleton • Carboxylated osteocalcin attracts Ca, enhances mineralization The Issues • Deficiency state (scurvy)—defective collagen matrix, bone resorption, osteoporosis, fractures The Issues • Undercarboxylated osteocalcin associated with bone • serum levels common in elderly, institutionalized resorption, fracture • Smoking intestinal absorption, increases catabolism • Low serum Vit K assoc with lower BMD, fracture risk • Vit C intake associated with BMD, bone loss, • Intervention studies mixed: BMD neg, fx + fractures Sources • K1:
Recommended publications
  • Potassium-Magnesium Citrate Is an Effective Prophylaxis Against Recurrent Calcium Oxalate Nephrolithiasis
    0022-5347/97/1586-2069$03.00/0 JOURNAL OF UROLOGY Vol. 158,2069-2073, December 1997 Copyright Q 1997 by AMERICANUROLOGICAL ASS~CIATION, INC. Printed in U.S.A. POTASSIUM-MAGNESIUM CITRATE IS AN EFFECTIVE PROPHYLAXIS AGAINST RECURRENT CALCIUM OXALATE NEPHROLITHIASIS BRUCE ETTINGER,* CHARLES Y. C. PAK, JOHN T. CITRON, CARL THOMAS, BEVERLEY ADAMS-HIJET AND ARLINE VANGESSEL From the Diuision of Research, Kaiser Permanente Medical Care Program, Oakland, California, the Department of Mineral Metabolism, Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, Department of Medicine, Kaiser Permanente Medical Center, Walnut Creek, California, Department of Urology, Kaiser Permanente Medical Center, San Francisco, California, and Kaiser Foundation Research Institute, Kaiser Foundation Hospitals, Oakland, California ABSTRACT Purpose: We examined the efficacy of potassium-magnesium citrate in preventing recurrent calcium oxalate kidney calculi. Materials and Methods: We conducted a prospective double-blind study of 64 patients who were randomly assigned to receive placebo or potassium-magnesium citrate (42 mEq. potassium, 21 mEq. magnesium, and 63 mEq. citrate) daily for up to 3 years. Results. New calculi formed in 63.6%of subjects receiving placebo and in 12.9%of subjects receiving potassium-magnesiumcitrate. When compared with placebo, the relative risk of treat- ment failure for potassium-magnesium citrate was 0.16 (95%confidence interval 0.05 to 0.46). potassium-magnesium citrate had a statistically significant effect (relative risk 0.10,95%confi- dence interval 0.03 to 0.36) even after adjustment for possible confounders, including age, pretreatment calculous event rate and urinary biochemical abnormalities.
    [Show full text]
  • Electro-Activation of Potassium Acetate, Potassium Citrate and Calcium
    Liato et al. SpringerPlus (2016) 5:1760 DOI 10.1186/s40064-016-3453-1 RESEARCH Open Access Electro‑activation of potassium acetate, potassium citrate and calcium lactate: impact on solution acidity, Redox potential, vibrational properties of Raman spectra and antibacterial activity on E. coli O157:H7 at ambient temperature Viacheslav Liato1,2, Steve Labrie1,3 and Mohammed Aïder1,2,4* *Correspondence: [email protected] Abstract 1 Institute of Nutrition and Functional Foods (INAF), Aims: To study the electro-activation of potassium acetate, potassium citrate and Université Laval, Quebec, QC calcium lactate aqueous solutions and to evaluate their antimicrobial effect against E. G1V 0A6, Canada coli O157:H7 at ambient temperature. Full list of author information is available at the end of the Methods and results: Potassium acetate, potassium citrate and calcium lactate aque- article ous solutions were electrically excited in the anodic compartment of a four sectional electro-activation reactor. Different properties of the electro-activated solutions were measured such as: solutions acidity (pH and titratable), Redox potential and vibrational properties by Raman spectroscopy. Moreover, the antimicrobial activity of these solu- tions was evaluated against E. coli O157:H7. The results showed a pH decrease from 7.07 0.08, 7.53 0.12 and 6.18 0.1 down to 2.82 0.1, 2.13 0.09 and 2.26 0.15, after ±180 min of electro-activation± ± of potassium acetate,± potassium± citrate and calcium± lactate solution, respectively. These solutions were characterized by high oxidative ORP of 1076 12, 958 11 and 820 14 mV, respectively.
    [Show full text]
  • Reflections on Dentifrice Ingredients, Benefits and Recommendations a Peer-Reviewed Publication Written by Fiona M
    Earn 4 CE credits This course was written for dentists, dental hygienists, and assistants. Reflections on Dentifrice Ingredients, Benefits and Recommendations A Peer-Reviewed Publication Written by Fiona M. Collins, BDS, MBA, MA This course has been made possible through an unrestricted educational grant from Colgate-Palmolive, Co. The cost of this CE course is $59.00 for 4 CE credits. Cancellation/Refund Policy: Any participant who is not 100% satisfied with this course can request a full refund by contacting PennWell in writing. Educational Objectives dentifrice use. Recommendations should be based on an The overall goal of this article is to provide dental profession- individual patient’s specific needs and desires as well as the als with information on the active and inactive ingredients in scientific support for a dentifrice. Both the Food and Drug dentifrices and their benefits. Administration (FDA) and the American Dental Associa- Upon completion of this course, the clinician will be able tion (ADA) have played roles in controlling (FDA) and ac- to do the following: cepting (ADA) dentifrices. 1. List active ingredients in dentifrices and their therapeutic benefits. Dentifrice Ingredients 2. List inactive ingredients in dentifrices and their functions. Dentifrices contain both active and inactive ingredients. Ac- 3. Know the roles of the FDA and ADA with respect to tive ingredients are those that offer a therapeutic benefit, while over-the-counter dentifrices. inactive ingredients are non-therapeutic and also contribute 4. Understand the considerations involved and importance of to the physicochemical properties of the dentifrice – its feel, recommending OTC dentifrices for individual patients.
    [Show full text]
  • Innovative Prolonged-Release Oral Alkalising Formulation
    www.nature.com/scientificreports OPEN Innovative prolonged‑release oral alkalising formulation allowing sustained urine pH increase with twice daily administration: randomised trial in healthy adults C. Guittet1, C. Roussel‑Maupetit1, M. A. Manso‑Silván 1, F. Guillaumin1, F. Vandenhende2 & L. A. Granier 1* A multi-particulate fxed-dose combination product, consisting of a combination of two alkalising salts formulated as prolonged-release granules, ADV7103, was developed to obtain a sustained and prolonged alkalising efect. The specifc release of both types of granules was shown in vitro through their dissolution profles, which indicated that potassium citrate was released within the frst 2–3 h and potassium bicarbonate up to 10–12 h after administration. The long-lasting coverage of ADV7103 was confrmed through a randomised, placebo-controlled, double-blind, two-period study, measuring its efect on urine pH in healthy adults (n = 16) at doses of alkalising agent ranging between 0.98 and 2.88 meq/kg/day. A signifcant increase of urine pH with a positive dose–response in healthy adult subjects was shown. Urine pH above 7 was maintained during 24 h with a dosing equivalent to 1.44 meq/kg twice a day, while urine pH was below 6 most of the time with placebo. The efect observed was non-saturating within the range of doses evaluated and the formulation presented a good safety profle. ADV7103 provided an efective prolonged release of alkalising salts to cover a 12-h efect with adequate tolerability and could aford a twice a day (morning and evening) dosing in patients requiring long-term treatment.
    [Show full text]
  • Calcium Chloride
    Electrolytes Livestock 1 2 Identification of Petitioned Substance 3 4 Chemical Names (Compiled from commercial 44 Calcium propionate, propanoic acid, calcium salt 5 electrolyte formulations): 45 Ca(CH3.CH2.COO)2 6 Calcium chloride (10043-52-4) 46 Calcium oxide, lime CaO 7 Calcium borogluconate (5743-34-0) 47 Calcium sulfate, gypsum CaSO4 8 Calcium gluconate (299-28-5) 48 9 Calcium hypophosphite (7789-79-9) 49 Magnesium diborogluconate, Mg[(HO.CH2CH 10 Calcium lactate (814-80-2) 50 (HBO3)CH(CH.OH)2 COO]2 11 Calcium phosphate tribasic (7758-87-4) 51 Magnesium citrate, Mg3(C6H5O7)2 12 Calcium phosphate dibasic (7757-93-9) 52 Magnesium hypophosphite Mg(H2PO2)2 13 Calcium phosphate monobasic (10031-30-8) 53 Magnesium sulfate, Epsom salts MgSO4 14 Calcium propionate (4075-81-4) 54 Potassium chloride KCl 15 Calcium oxide (1305-78-8) 55 Potassium citrate, K3(C6H5O7) 16 Calcium sulfate (7778-18-19) 56 Tripotassium phosphate K3(PO4) 17 Magnesium borogluconate (not available) 57 Dipotassium hydrogen phosphate K2HPO4 18 Magnesium citrate, tribasic (3344-18-1) 58 Potassium dihydrogen phosphate KH2PO4 19 Magnesium hypophosphite (10377-57-8) 59 Sodium acetate Na(CH3COO) 20 Magnesium sulfate (7487-88-9) 60 Sodium bicarbonate, baking soda NaHCO3 21 Potassium chloride (7447-40-7) 61 Sodium chloride, table salt, NaCl 22 Potassium citrate (866-84-2) 62 Sodium citrate, trisodium citrate Na3(C6H5O7) 23 Potassium phosphate, tribasic (7778-53-2) 63 Trisodium phosphate Na3(PO4) 24 Potassium phosphate, dibasic (7758-11-4) 64 Disodium hydrogen phosphate Na2HPO4 25 Potassium phosphate, monobasic (7778-77-0) 65 Sodium dihydrogen phosphate NaH2PO4 26 Sodium acetate (127-09-3) 66 27 Sodium bicarbonate (144-55-8) 67 Trade Names: 28 Sodium chloride (7647-14-5) 68 These individual electrolyte salts are not sold 29 Sodium citrate (68-04-2) 69 with Trade Names.
    [Show full text]
  • POTASSIUM CHLORIDE EXTENDED-RELEASE CAPSULES, USP, 8 Meq 1
    174931-1 Front 10" X 10" Fold 1.25" X 1.25" Prints Black 10/14/09 POTASSIUM CHLORIDE EXTENDED-RELEASE CAPSULES, USP, 8 mEq 1. For the treatment of patients with hypokalemia with or without ic inspection before and after one week of solid oral potassium chlo­ and 10 mEq metabolic alkalosis, in digitalis intoxications, and in patients with ride therapy. The ability of this model to predict events occurring in hypokalemic familial periodic paralysis. If hypokalemia is the result usual clinical practice is unknown. Trials which approximated usual Only of diuretic therapy, consideration should be given to the use of a clinical practice did not reveal any clear differences between the wax lower dose of diuretic, which may be sufficient without leading to matrix and microencapsulated dosage forms. In contrast, there was DESCRIPTION: hypokalemia. a higher incidence of gastric and duodenal lesions in subjects receiv­ Potassium Chloride Extended-release Capsules, USP, 8 mEq and 10 mEq ing a high dose of a wax matrix controlled-release formulation under are oral dosage forms of microencapsulated potassium chloride 2. For the prevention of hypokalemia in patients who would be at conditions which did not resemble usual or recommended clinical containing 600 and 750 mg, respectively, of potassium chloride particular risk if hypokalemia were to develop e.g., digitalized practice (i.e., 96 mEq per day in divided doses of potassium chloride USP equivalent to 8 and 10 mEq of potassium. patients or patients with significant cardiac arrhythmias, hepatic cir­ administered to fasted patients, in the presence of an anticholinergic rhosis with ascites, states of aldosterone excess with normal renal drug to delay gastric emptying).
    [Show full text]
  • Calcium Citrate in Fortified-Food Applications
    Calcium Citrate in Fortified-Food Applications By Gerhard Gerstner, Ph.D. Contributing Editor alcium is a key mineral in the human body, necessary for the normal growth and C development of the skele- ton as well as for teeth, nerve, muscle and enzyme functions. As the body’s calcium absorption capabilities reduce with age, it is vital for older individuals to have a suffi- cient calcium intake. Calcium require- ments vary throughout an individual’s life and for different population groups. However, it is generally evident that a significant proportion of the population in Western countries fails to achieve the recommended calcium intakes. Poor dietary habits are seen to be responsible for this situation, especially when fast- food consumption dominates much of the population’s menu. Various studies, including “The Min- eral Fortification of Foods,” published in 1999 by Leatherhead International in its anhydrous form, as well as cal- Optimal Daily Calcium Intake cium lactate gluconate. Tricalcium citrate (TCC), com- According to NIH Recommendations monly referred to as calcium citrate, is a high-quality calcium source for Calcium (mg/day) food fortification. Its main character- istics are good solubility at low pH, a Infants, up to six months . .400 neutral taste and flavor profile, high Infants, six to 12 months . .600 calcium content and excellent bio- availability. Besides the standard pow- Infants, one to 10 years . .800 der product, TCC is also supplied as Children and young adults, 11 to 24 years . .1,200 to 1,500 a micronized (ultra-fine) granulation Adults, 25 to 65 years . .1,000 that will dissolve even more quickly in acidic applications.
    [Show full text]
  • “Inert” Ingredients Used in Organic Production
    “Inert” Ingredients Used in Organic Production Terry Shistar, PhD A Beyond Pesticides Report he relatively few registered pesticides allowed in organic production are contained in product formulations with so-called “inert” ingredients that are not disclosed on the T product label. The “inerts” make up the powder, liquid, granule, or spreader/sticking agents in pesticide formulations. The “inerts” are typically included in products with natural or synthetic active pesticide ingredients recommended by the National Organic Standards Board (NOSB) and listed by the National Organic Program (NOP) on the National List of Allowed and Prohibited Substances. Any of the pesticides that meet the standards of public health and environmental protection and organic compatibility in the Organic Foods Production Act (OFPA) may contain “inert” ingredients. Because the standards of OFPA are different from those used by the U.S. Environmental Protection Agency (EPA) to regulate pesticides and given changes in how the agency categorizes inerts, the NOSB has adopted a series of recommendations since 2010 that established a substance review process as part of the sunset review. NOP has not followed through on the Board’s recommendations and, as a result, there are numerous materials in use that have not been subject to OFPA criteria. This report (i) traces the history of the legal requirements for review by the NOSB, (ii) identifies the universe of toxic and nontoxic materials that make of the category of “inerts” used in products permitted in organic production, and (iii) suggests a path forward to ensure NOSB compliance with OFPA and uphold the integrity of the USDA organic label.
    [Show full text]
  • On the Safety Assessment of Citric Acid, Inorganic Citrate Salts, and Alkyl Citrate Esters As Used in Cosmetics
    Final Report On the Safety Assessment of Citric Acid, Inorganic Citrate Salts, and Alkyl Citrate Esters as Used in Cosmetics March 27, 2012 The 2012 Cosmetic Ingredient Review Expert Panel members are: Chair, Wilma F. Bergfeld, M.D., F.A.C.P.; Donald V. Belsito, M.D.; Ronald A. Hill, Ph.D.; Curtis D. Klaassen, Ph.D.; Daniel Liebler, Ph.D.; James G. Marks, Jr., M.D., Ronald C. Shank, Ph.D.; Thomas J. Slaga, Ph.D.; and Paul W. Snyder, D.V.M., Ph.D. The CIR Director is F. Alan Andersen, Ph.D. This report was prepared by Monice M. Fiume, Senior Scientific Analyst/Writer and Bart A. Heldreth, Ph.D., Chemist. © Cosmetic Ingredient Review 1101 17th Street, NW, Suite 412 ♢ Washington, DC 20036-4702 ♢ ph 202.331.0651 ♢ fax 202.331.0088 ♢ [email protected] ABSTRACT: The CIR Expert Panel assessed the safety of citric acid, 12 inorganic citrate salts, and 20 alkyl citrate esters as used in cosmetics, concluding that these ingredients are safe in the present practices of use and concentration. Citric acid is reported to function as a pH adjuster, chelating agent, or fragrance ingredient. Some of the salts are also reported to function as chelating agents, and a number of the citrates are reported to function as skin conditioning agents. The Panel reviewed available animal and clinical data; because, citric acid, calcium citrate, ferric citrate, manganese citrate, potassium citrate, sodium citrate, diammonium citrate, isopropyl citrate, stearyl citrate, and triethyl citrate are GRAS direct food additives, dermal toxicity was the focus for these ingredients in this assessment.
    [Show full text]
  • The Effect of a Dietary Supplement of Potassium Chloride Or Potassium Citrate
    Downloaded from https://www.cambridge.org/core British Journal of Nutrition (2008), 99, 1284–1292 doi: 10.1017/S0007114507864853 q The Authors 2007 The effect of a dietary supplement of potassium chloride or potassium citrate . IP address: on blood pressure in predominantly normotensive volunteers 170.106.40.139 Alessandro Braschi and Donald J. Naismith* Department of Nutrition and Dietetics, King’s College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NN, UK , on 30 Sep 2021 at 17:27:21 (Received 12 May 2007 – Revised 9 October 2007 – Accepted 11 October 2007 – First published online 6 December 2007) Blood pressure (BP) shows a continuous relationship with the risk of CVD. There is substantial evidence that dietary potassium exerts an anti- pressor effect. Most clinical trials have used KCl. However, the chloride ion may have a pressor effect and in foods potassium is associated with organic anions. In a double-blind randomized placebo-controlled trial we explored the effect on BP of two salts of potassium, KCl and pot- , subject to the Cambridge Core terms of use, available at assium citrate (K-cit), in predominantly young healthy normotensive volunteers. The primary outcome was the change in mean arterial pressure as measured in a clinic setting. After 6 weeks of supplementation, compared with the placebo group (n 31), 30 mmol K-cit/d (n 28) changed mean arterial pressure by 25·22 mmHg (95 % CI 28·85, 24·53) which did not differ significantly from that induced by KCl (n 26), 24·70 mmHg (26·56, 22·84). The changes in systolic and diastolic BP were 26·69 (95 % CI 28·85, 24·43) and 24·26 (95 % CI 26·31, 22·21) mmHg with K-cit and 25·24 (95 % CI 27·43, 23·06) and 24·30 (95 % CI 26·39, 22·20) mmHg with KCl, and did not differ significantly between the two treatments.
    [Show full text]
  • Chapter 6 |Management of Morbidity
    NATIONAL MEDICAL CARE STATISTICS 2010 CHAPTER 6 | MANAGEMENT OF MORBIDITY 6.1 PRESCRIBED MEDICATION Anatomical Therapeutic Chemical (ATC) Classification System The drugs prescribed in a primary care setting were coded according to the ATC classification, which categorises the active ingredients into different groups according to the body system or organ on which they exert their effects as well as their chemical, pharmacological and therapeutic properties. According to the code, each drug is classified at five different levels. first Level is the main group, which consists of mostly organs or body systems. Each of the 14 main groups in Level 1 are divided at 2nd Level according to their pharmacological and therapeutic effects, which are further subdivided at 3rd and 4th levels based on their chemical, pharmacological and therapeutic properties. The 5th Level of the code indicates the chemical substance1. An example of ATC classification for amlodipine is shown below. The full ATC code for plain amlodipine products is thus C08CA01. LEVELS ATC CODE ATC DESCRIPTION 1 C Cardiovascular system 2 C08 Calcium channel blockers 3 C08C Selective calcium channel blockers with mainly vascular effects 4 C08C A Dihydropyridine derivatives 5 C08C A01 Amlodipine Types of Drugs Prescribed A total of 54,532 drugs were prescribed in NMCS 2010, out of which 54,204 drugs (99.4%) were coded according to the ATC classification. The remaining 328 drugs could not be coded due to illegible writing or spelling errors. In this report, data is being presented according to the main groups (ATC Level 1 – Table 6.1) and main therapeutic groups (ATC Level 2 – Table 6.2) followed by a list of Top 100 most prescribed medications, in descending order (Table 6.3).
    [Show full text]
  • FCC 10, Second Supplement the Following Index Is for Convenience and Informational Use Only and Shall Not Be Used for Interpretive Purposes
    Index to FCC 10, Second Supplement The following Index is for convenience and informational use only and shall not be used for interpretive purposes. In addition to effective articles, this Index may also include items recently omitted from the FCC in the indicated Book or Supplement. The monographs and general tests and assay listed in this Index may reference other general test and assay specifications. The articles listed in this Index are not intended to be autonomous standards and should only be interpreted in the context of the entire FCC publication. For the most current version of the FCC please see the FCC Online. Second Supplement, FCC 10 Index / Allura Red AC / I-1 Index Titles of monographs are shown in the boldface type. A 2-Acetylpyrrole, 21 Alcohol, 90%, 1625 2-Acetyl Thiazole, 18 Alcohol, Absolute, 1624 Abbreviations, 7, 3779, 3827 Acetyl Valeryl, 608 Alcohol, Aldehyde-Free, 1625 Absolute Alcohol (Reagent), 5, 3777, Acetyl Value, 1510 Alcohol C-6, 626 3825 Achilleic Acid, 25 Alcohol C-8, 933 Acacia, 602 Acid (Reagent), 5, 3777, 3825 Alcohol C-9, 922 ªAccuracyº, Defined, 1641 Acid-Hydrolyzed Milk Protein, 22 Alcohol C-10, 390 Acesulfame K, 9 Acid-Hydrolyzed Proteins, 22 Alcohol C-11, 1328 Acesulfame Potassium, 9 Acid Calcium Phosphate, 240 Alcohol C-12, 738 Acetal, 10 Acid Hydrolysates of Proteins, 22 Alcohol C-16, 614 Acetaldehyde, 11 Acidic Sodium Aluminum Phosphate, Alcohol Content of Ethyl Oxyhydrate Acetaldehyde Diethyl Acetal, 10 1148 Flavor Chemicals (Other than Acetaldehyde Test Paper, 1636 Acidified Sodium Chlorite
    [Show full text]